-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 26, 2021, Agenus announced that its anti-PD-1 monoclonal antibody batilimumab (balstilimab), a single-drug treatment of recurrent/metastatic cervical cancer, was published online in the international peer-reviewed journal.
Gynecologic Oncology
.
Batilizumab is a fully human monoclonal immunoglobulin G4 (IgG4) antibody, designed to target and inhibit the interaction of PD-1 and its ligands PD-L1 and PD-L2 to activate the immune system to attack tumors
.
It is worth mentioning that in June 2020, Betta Pharmaceuticals reached a strategic cooperation with Agenus, and obtained the drug in the Greater China region, single drug or combined with other drugs to treat all tumors except intravesical administration.
In this open-label, single-arm global phase 2 clinical trial, the trial results showed that among 140 evaluable patients, the objective response rate (ORR) of PD-L1 positive tumor patients was 20.
0%, including 3 cases Patients (3/85, 3.
5%) had complete remission, and 14 patients (14/85, 16.
5%) showed partial remission
.
At a median follow-up time of 14.
The ORR of confirmed PD-L1 positive or negative tumor patients was 15.
0%, including 5 patients (3.
6%) with complete remission and 16 patients (11.
4%) with partial remission
.
The median DoR was 15.
It is worth noting that the drug has been observed to respond in all histological subgroups of cervical cancer, including patients who did not respond to other therapies
.
This indicates that compared with currently approved PD-1 inhibitors, batirizumab may be a differentiated anti-PD-1 antibody
Reference materials:
[1] Balstilimab Monotherapy Data Published in Gynecologic Oncology.
(The original text has been deleted)
